Publisher Correction: Suspect screening analysis to improve untargeted and targeted UHPLC-qToF approaches: the biodegradability of a proton pump inhibitor medicine and a natural medical device
Luisa Mattoli, Giacomo Proietti, Giada Fodaroni, Claudio Marzio Quintiero, Michela Burico, Mattia Gianni, Emiliano Giovagnoni, Valentino Mercati, Claudio Santi
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsBiosimilars and Bioanalytical Methods
Correction to:* Scientific Reports* 10.1038/s41598-023-49948-8, published online 02 January 2024
The Competing interests section in the original version of this Article was incorrect.
“The authors declare no competing interests.”
now reads:
“The authors listed below report the following details of affiliation or involvement in an organization or entity with a financial interest in the subject matter or materials discussed in this manuscript.
LM, GP, GF, CMQ, GF, MB, GM are employed in Aboca who produce and commercialize the product indicated in the manuscript as B. VM is Honorary President of Aboca SPA. CS is the scientific responsible of a project related to the topic of the present manuscript and committed by Aboca to C.E.M.I.N (UniPG). Product A is a generic drug containing Omeprazole, while “Product B”, Neobianacid, is a Medical device made of substances. Both products are indicated for the treatment reflux diseases and functional dyspepsia.”
The original Article has been corrected.